Plasma Fractionation Market In-Depth Analysis Globally by Top Key Players
The plasma fractionation market is projected to grow at a
6.5% CAGR between 2018-2023, reveals the new Market Research Future (MRFR)
report. Plasma is a component in the blood that has thousands of proteins, of
which just a handful of 20 is used for producing therapeutic plasma products.
The process to separate, extract, and purify these proteins from the plasma is
known as fractionation process. They fit into three classes- albumin that is
used for treating fluid loss or supplementing low albumin levels, clotting
factors that are used for treating hemophilia & other bleeding disorders,
and immunoglobulins that are used for enhancing the immune response to disease
as well as treat auto-immunity. It has wide applications in hemato-oncology,
rheumatology, pulmonology, critical care, hematology, neurology, immunology,
and others.
Numerous factors are adding to the global plasma
fractionation market. Such factors, according to the recent MRFR report,
include rising incidence of autoimmune and respiratory disorders, rising plasma
collection, technological advancements, increasing geriatric population, and
increasing participation of top market players. Additional factors adding to
the global plasma fractionation market growth include the rising usage of
plasma proteins to diagnose and treat various complex disorders, rising
research and development to create plasma-based products, rising usage of
immunoglobulins in different therapeutic applications, growing geriatric
population, and increase in plasma collection centers.
On the contrary, unfavorable reimbursement policies, the
high price of advanced products, and the availability of recombinant
alternatives are factors that may limit the global plasma fractionation market
growth over the forecast period.
Request
Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/7397
Market Segmentation
The MRFR report provides an inclusive segmental analysis of
the global plasma fractionation market based on end user, application, and
product.
By product, the global plasma fractionation market is
segmented into protease inhibitors, albumin, coagulation factor concentrates,
immunoglobulin, and others. Immunoglobulin is again segmented into subcutaneous
immunoglobulin (SCIG), intravenous immunoglobulin (IVIG), and others.
Coagulation factor is again segmented into Factor XIII, fibrinogen
concentrates, prothrombin complex concentrate, von Willebrand factor, factor
IX, and factor VIII. Of these, the von Willebrand factor will lead the market
over the forecast period.
By application, the global plasma fractionation market is
segmented into hemato-oncology, rheumatology, pulmonology, critical care,
hematology, neurology, immunology, and others. Of these, the neurology segment
will dominate the market over the forecast period.
By end user, the global plasma fractionation market is
segmented into academic institutes, clinical research laboratories, hospitals
and clinics, and others. Of these, hospitals and clinics will have a major
share in the market over the forecast period.
Regional Analysis
By region, the global plasma fractionation market covers the
growth opportunities and recent trends across Europe, the Americas, the Middle
East & Africa (MEA), and the Asia Pacific (APAC). Of these, the Americas
will lead the market over the forecast period. Factors adding to the growth of
the plasma fractionation market in the region include the rising incidence of
immunodeficiency disorders and the presence of leading market players.
The plasma fractionation market in Europe is predicted to
hold the second-largest share over the forecast period for the increasing
research and development investments and rising technological advancements.
The plasma fractionation market in the APAC region is
predicted to grow at the fastest pace over the forecast period for the
increasing healthcare expenditure.
The plasma fractionation market in the MEA is predicted to
have a small share over the forecast period for the inadequate economic development
in the African region.
Key Players
Key players profiled in the plasma fractionation market
report comprise Shire, Shanghai RAAS, Sanquin, Octapharma AG, LFB group,
Kedrion S.p.A, Japan Blood Products Organization, Grifols, S.A., Green Cross
Corporation, CSL Limited, China Biologic Products Holdings, Inc., Biotest AG,
and Bio Products Laboratory (BPL).
Browse Detailed TOC
with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/plasma-fractionation-market-7397
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to
unravel the complexity of various industries through our Cooked Research Report
(CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR
team have supreme objective to provide the optimum quality market research and
intelligence services to our clients.
Contact:
Akash Anand
Market Research Future
+1 646 845 9312
Email: sales@marketresearchfuture.com
Comments
Post a Comment